Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Daratumumab for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
New York, New York
This trial will study the effects of daratumumab on metastatic NSCLC patients with an STK11/LKB1 mutation. It will measure if a response rate of ≥20% is clinically meaningful.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service